Restart Life Sciences Announces Closing First Tranche of Financing

Rhea-AI Summary

Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.

Positive

• Raised CDN$500,000 in first tranche financing
• Issued 5,000,000 units at CAD$0.10 each
• Proceeds allocated to health food trials and acquisitions

Negative

• Potential dilution of 5,060,000 additional shares via warrants
• Paid CAD$16,800 cash in finder's fees
• Warrants exercisable at low strike of CAD$0.10 for one year

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement").

Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per Unit. Each Unit consists of one common share and one transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share for a period of one (1) year at a price of CAD $0.10 per common share.

In connection with the Placement, the Company paid cash finder's fees totaling CAD $16,800 and issued 60,000 non-transferable finder warrants (each, a "Finder Warrant") to certain eligible arm's-length finders who introduced subscribers to the Placement. Each Finder Warrant entitles the holder to purchase one common share for a period of one (1) year at a price of CAD $0.10 per common share.

The Company intends to use the proceeds from the Offering towards health food trials, potential acquisitions, and general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on April 6, 2026.

About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.

On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co

Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277058

FAQ

What did Restart Life Sciences (NMLSF) announce on December 5, 2025?

Restart Life closed a CDN$500,000 first tranche private placement issuing 5,000,000 units at CAD$0.10 per unit.

How are the units structured in Restart Life's NMLSF financing?

Each unit contains one common share plus one transferable warrant exercisable at CAD$0.10 for one year.

What is the hold period and expiry date for securities from Restart Life's placement (NMLSF)?

All securities are subject to a four-month-and-one-day hold period ending on April 6, 2026.

How will Restart Life (NMLSF) use the proceeds from the CDN$500,000 placement?

The company intends to use proceeds for health food trials, potential acquisitions, and general working capital.

What finder compensation did Restart Life pay in the NMLSF placement?

The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants.

How much potential dilution could Restart Life (NMLSF) face from this financing?

Warrants issued could convert to 5,060,000 additional shares (5,000,000 unit warrants plus 60,000 finder warrants) at CAD$0.10 within one year.